DXY Insight Database is a leading global drug competitive intelligence platform with deep China insights, delivering multi-dimensional intelligence across the entire drug lifecycle — from preclinical research through post-market approval — and empowering enterprises to make more precise decisions and work more efficiently. Key highlights include: · 80,000+ drug pipelines (22,000+ originated by Chinese companies) · 25,000+ pharmaceutical companies (11,000+ based in China) · Tracking of 9,000+ targets and 14,000+ BD transactions
CRQA
CRQA: Your Trusted GxP Compliance and Regulatory Consulting Partner Company: CRQA (Compliance, Regulatory & Quality Assurance) Headquarters: Noida, Uttar Pradesh, India (Office No. 602, 6th Floor, Tower B, B8 Noida One, Sector 62) Website: www.crqa.in Contact: bd@crqa.in | +91 98100 68241 Tagline: GxP Compliance: We have got you covered Who We Are CRQA is an independent, specialized auditing and regulatory consulting organization headquartered in New Delhi/Noida, India. Unlike large contract research organizations (CROs) that offer quality assurance as an add-on, CRQA was built exclusively around GxP compliance — making regulatory excellence our sole focus, not a side offering. Registered with Dun & Bradstreet, ISO 13485 & ISO 9011:2015 certified, and recognized as an MSME, CRQA has positioned itself as a credible and conflict-free compliance partner for pharmaceutical companies, biotechnology firms, clinical research organizations, medical device manufacturers, and healthcare institutions worldwide. Global Reach CRQA operates across more than 60 countries and delivers its services in 30 languages, making it one of the most geographically diverse independent GxP auditing firms in the world. Our network of Auditors spans: • Asia: India, Japan, China, Southeast Asia, including major Indian cities — New Delhi NCR, Noida, Gurgaon, Mumbai, Pune, Bangalore, Chennai, Hyderabad, Kolkata, Ahmedabad, Vadodara • Americas: United States, Latin America • Europe: EU countries, UK • Middle East & Africa • Australia & Oceania This wide geographical presence enables us to deploy region-based auditors who understand local regulatory environments — reducing travel costs and turnaround time for our clients. Why CRQA? — The Value Proposition CRQA was founded to address a critical gap in the pharmaceutical services industry: the absence of a dedicated, independent auditing agency free from conflicts of interest. Key advantages of working with CRQA: ✔ No conflict of interest — CRQA is purely an auditing and consulting firm; we do not run clinical trials or offer CRO services, ensuring full objectivity in every audit. ✔ Specialized expertise — Our auditors are seasoned professionals with deep GxP knowledge, offering a level of focus that generalist CROs cannot match. ✔ Cost efficiency — With locally based auditors across 60+ countries, clients benefit from significant cost savings on travel and logistics. ✔ Better sponsor–CRO relationships — By outsourcing audits to CRQA rather than using competitor CROs, sponsors can maintain neutral, healthy vendor relationships. ✔ Holistic compliance perspective — Our external auditors provide an unbiased, big-picture view of a client’s systems, identifying gaps and improvement opportunities that internal teams may overlook. Services Portfolio CRQA provides a comprehensive suite of GxP auditing and regulatory consulting services: Clinical & Research Compliance • GCP (Good Clinical Practice) Audits and Services • GCP Consultancy • Mock Inspections • BA/BE (Bioavailability/Bioequivalence) CRO Audits • Remote GCP and Pharmacovigilance Audits • Vendor Audits • Study Audits Manufacturing & Distribution Quality • GMP (Good Manufacturing Practice) Audits and Services • GDP (Good Distribution Practice) Compliance • GLP/GCLP (Good Laboratory/Clinical Laboratory Practice) Audits • Pharmaceutical Quality Management Services Pharmacovigilance & Drug Safety • Pharmacovigilance Audits • QPPV (Qualified Person for Pharmacovigilance) Services • Global Pharmacovigilance Outsourcing Services Medical Devices • Medical Device Regulatory Audits and Consulting • ISO 13485 Quality Management System Support Regulatory Affairs & Strategy • Regulatory Pathway Consulting Services • Global Pharmaceutical Outsourcing Services • Dossier Submission Support (Feasibility to Filing) • Qualified Person (QP) Services in Europe Technology & Systems Compliance • Computer System Validation (CSV) • Compliance Training on 21 CFR Part 11 Quality Systems & SOPs • Quality Management and Compliance Systems • SOPs Development and Review Training & Education • Online Training and Workshops • Ethics Committee / IRB Training • Compliance Training Programs Key Clients CRQA has earned the trust of a diverse global clientele, including recognized names across pharma, biotech, medical devices, and healthcare and have worked with wide range of pharma, biopharma and medical device clients from USA, Europe, India. Certifications & Recognition • D-U-N-S Registered (Dun & Bradstreet Verified) • ISO 13485 Certified (Medical Devices Quality Management Systems) • ISO 9001 : 2015 • MSME Recognized (Government of India) Our Differentiator at BIO USA At a conference where partnerships are forged and life sciences innovation meets business strategy, CRQA stands out as the go-to independent partner for: • Pharma and biotech companies entering new markets who need local regulatory audit support • CROs and sponsors seeking objective, third-party GxP compliance evaluations • Medical device companies needing ISO 13485 audits and regulatory consulting • Global life sciences firms looking for cost-effective, scalable compliance solutions across multiple geographies Whether you are preparing for an FDA, EMA, or CDSCO inspection, building your quality management infrastructure, or seeking ongoing pharmacovigilance oversight — CRQA delivers expert, independent, and conflict-free compliance support. Connect With Us at BIO USA kshahani@crqa.in +91 98100 68241 www.crqa.in LinkedIn: CRQA India CRQA — GxP Compliance: We Have Got You Covered.
Barrington James
Barrington James are an industry leading, global recruitment business that exclusively serves the Pharmaceutical, Biotechnology and Medical Device sectors. With offices all over the world and hundreds of specialists dedicated to sourcing exceptional talent, we have the capacity and capabilities to deliver world-class recruitment solutions to Life Science companies of all sizes.
Accelsiors Gmbh
Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2025 in the German Pavilion to explore how we can advance your next clinical breakthrough. At Accelsiors CRO, we accelerate biopharmaceutical innovation through a science-driven, patient-centric approach. As a global, full-service CRO, we provide tailored clinical trial solutions designed to de-risk development, optimize timelines, and bring transformative therapies to market faster. With a proven track record in global clinical development, we navigate the complexities of modern drug research—from early-stage clinical development to regulatory approvals and patient-centric trials. Our strategic approach, cutting-edge AI analytics, and deep therapeutic expertise ensure seamless execution and measurable outcomes. | Accelsiors CRO – Science-Driven Clinical Excellence Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2026 in the German Pavilion to explore how we can advance your next clinical breakthrough. Let’s discuss how we can accelerate your next clinical breakthrough with Accelerant™, our proprietary Penta-Helix approach—a unique integration of science, patient-centricity, Quality by Design, AI-driven state-of-the-art technologies, and speed with cost-effectiveness at every stage of clinical development.
A2 Healthcare
A2 Healthcare（A2）, a Japan-Taiwan industry leader for clinical development, spearheads global new drug development in Japan from its new US office in Boston area. A2 is the expert for clinical development in Japan and Taiwan. We are interested to invest in our partner’s pipeline for entering drug development, especially for drugs which are already marketed or under development outside of Japan. Clinical Development: A2 is the leading Japanese CRO providing contracted services in the clinical stage. A2 have the capability and experience to support our partners from early to late phases in any therapeutic area, as well as regulatory consultation and submission. A2 is a subsidiary of ITOCHU Corporation which is one of the largest Japanese company and were awarded the Best CRO of the Citeline Intelligence Award 2023. Pipeline Investment A2’s “Pipeline Accelerator Program (PAP)” supports the development of novel drug candidates enter Japanese market by becoming co-developers with the sponsor. In other words, we will invest in your clinical development cost. Through the program, we will enable domestic and foreign biotech startups as well as pharmaceutical companies for entering the Japanese market with a much lower hurdle. | A2 Healthcare Corporation (A2) is a Japan-based full-service CRO and a core member of the ITOCHU Group, one of the largest Japanese trading and investment conglomerates. With approximately 1,300 employees and offices in Tokyo (HQ), Osaka, Taiwan, and Boston, we focus on helping overseas biotech and pharma companies enter and succeed in the Japanese and Taiwanese markets. A2 has been recognized for excellence in clinical operations and partner satisfaction, receiving the Best CRO/CDMO award (2023) and Best Contract Research Organization award (2025) at the Citeline Pharma Intelligence / Citeline Japan Awards. Key points about A2, the ITOCHU Group and our Japan-entry platform: ◆A2 operates J-STEP (Japan Strategic Entry Platform), a one-stop service platform developed together with ITOCHU to support overseas companies across the full product lifecycle in Japan. ◆J-STEP services include: -Japan market and regulatory assessment, PMDA / ICCC strategy, and early pricing and access considerations. -Japan clinical development planning and execution aligned with global programs. -CMO/CDMO coordination and supply chain support tailored to modality. -NDA support, PMS, real-world evidence (RWE) studies, safety, logistics, and MAH services. -Business development and out-licensing support to Japanese pharma companies using ITOCHU’s local network. ◆In 2026, ITOCHU Corporation acquired 100% of CoreMed Co., Ltd., a leading Japanese regulatory and development-strategy consulting firm. ◆CoreMed provides consulting from early development strategy and CMC evaluation through PMDA consultations and marketing authorization applications, supported by a strong network with EU and US regulatory experts. ◆By combining CoreMed’s regulatory and scientific expertise with A2’s clinical operational capabilities, the ITOCHU Group offers integrated “Strategy + Execution” support for Japan, from first regulatory assessment to approval and post-marketing. ◆Therapeutic area experience spans oncology, rare diseases, regenerative medicine and ATMPs, infectious diseases and vaccines, as well as major and specialty indications. ◆Phase I through Phase III, PMS, and RWE studies, including: -Regulatory and clinical strategy development. -PMDA meeting preparation and briefing packages. -Site selection, site management, monitoring, data management, biostatistics, medical writing, safety, and project management. -ICCC coordination and regulatory submissions. -Post-marketing surveillance and observational research. ◆As part of the ITOCHU Group, A2 can also support: -Partnering and out-licensing between overseas biotech and Japanese pharma. -Flexible collaboration models such as co-development, risk sharing, and selective financial support for Japan-focused assets. -Strategic use of ITOCHU’s global networks, including ITC Venture Partners in Silicon Valley and A2’s Boston office. ◆We are looking to connect with: -Overseas biotech and pharma companies seeking a Japan development and regulatory partner. -Companies interested in one-stop Japan market entry using J-STEP. -Partners exploring co-development, risk sharing, or out-licensing opportunities for the Japanese market. Our goal is Your Goal.